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Background and Purpose: End-of-procedure substantial reperfusion [modified
Treatment in Cerebral Ischemia (mTICI) 2b-3], the leading endpoint for thrombectomy
studies, has several limitations including a ceiling effect, with recent achieved rates of
∼90%. We aimed to identify a more optimal definition of angiographic success along two
dimensions: (1) the extent of tissue reperfusion, and (2) the speed of revascularization.
Methods: Core-lab adjudicated TICI scores for the first three passes of EmboTrap
and the final all-procedures result were analyzed in the ARISE II multicenter study. The
clinical impact of extent of reperfusion and speed of reperfusion (first-pass vs. later-pass)
were evaluated. Clinical outcomes included 90-day functional independence [modified
Rankin Scale (mRS) 0–2], 90-day freedom-from-disability (mRS 0–1), and dramatic early
improvement [24-h National Institutes of Health Stroke Scale (NIHSS) improvement ≥
8 points].
Results: Among 161 ARISE II subjects with ICA or MCA M1 occlusions, reperfusion
results at procedure end showed substantial reperfusion in 149 (92.5%), excellent
reperfusion in 121 (75.2%), and complete reperfusion in 79 (49.1%). Reperfusion rates
on first pass were substantial in 81 (50.3%), excellent reperfusion in 62 (38.5%), and
complete reperfusion in 44 (27.3%). First-pass excellent reperfusion (first-pass TICI 2c-
3) had the greatest nominal predictive value for 90-day mRS 0–2 (sensitivity 58.5%,
specificity 68.6%). There was a progressive worsening of outcomes with each additional
pass required to achieve TICI 2c-3.
Yoo et al. First-Pass TICI 2c-3: Preferred Endpoint
Conclusions: First-pass excellent reperfusion (TICI 2c-3), reflecting rapid achievement
of extensive reperfusion, is the technical revascularization endpoint that best predicted
functional independence in this international multicenter trial and is an attractive
candidate for a lead angiographic endpoint for future trials.
Clinical Trial Registration: http://www.clinicaltrials.gov, identifier NCT02488915.
Keywords: intra-arterial therapy, reperfusion grading, reperfusion, brain ischaemia, cerebral infacrction, stent
retriever, mechanical thrombectomy
INTRODUCTION
The current consensus statement-endorsed benchmark
for procedural success after intra-arterial stroke therapy
(IAT) is procedure end substantial reperfusion [modified
Treatment in Cerebral Ischemia (mTICI) score of 2b or
higher], defined as the restoration of anterograde tissue
perfusion in more than 50% of the target downstream territory
(1, 2). The impressive clinical benefits observed in recent
thrombectomy trials reflected improved reperfusion with
second generation devices, most notably stent retrievers
(3, 4). Since these pivotal trials, there has been a further
increase in reported rates of substantial reperfusion
(5). In the recent ARISE (Analysis of Revascularization
in Ischemic Stroke with EmboTrap) II study, the core
lab-adjudicated TICI 2b-3 rate at procedure end was
92.5% (6).
However, there are considerable limitations to using the rate
of TICI 2b-3 as a lead technical efficacy endpoint for IAT trials.
First, this endpoint counts moderate reperfusion as a success,
but when reperfusion is only 50–90% achieved, substantial tissue
volumes remain in jeopardy. Second, the outcome of TICI 2b-3 is
considered a success regardless of the number of passes required
to achieve it, but maximal benefit is likely to be conferred by
first-pass success, thus reducing ischemia duration (7). Third,
the high rate of TICI 2b-3 seen with modern endovascular
technology results in a ceiling effect, making the measure
insensitive to further improvements in endovascular technique.
Accordingly, a reevaluation of the optimal angiographic endpoint
is necessary.
Using core-lab adjudicated data from ARISE II, we aimed to
assess the clinical impact of the first-pass effect (FPE) and to
identify the optimal definition of angiographic success along two
dimensions: (1) the extent of tissue reperfusion, and (2) the speed
of revascularization.
Abbreviations: ARISE II, Analysis of Revascularization in Ischemic Stroke with
EmboTrap II study; ASPECTS, Alberta Stroke Program Early CT Score; ASTER,
Direct Aspiration First Pass Technique for Thrombectomy Revascularisation of
Large Vessel Occlusion in Acute Ischaemic Stroke; FP, first pass; FPE, first pass
effect; HERMES, Highly Effective Reperfusion evaluated in Multiple Endovascular
Stroke Trials Collaboration; IAT, intra-arterial stroke therapy; ICA, internal
carotid artery; IQR, interquartile range; MCA, middle cerebral artery; mTICI,
modified Treatment in Cerebral Ischemia; ROC, receiver-operating characteristic
curve; sICH, symptomatic intracranial hemorrhage; TICI, Treatment in Cerebral
Ischemia.
MATERIALS AND METHODS
All data generated or analyzed during this study are included
in this published article and its Supplementary Material. The
ARISE II study design and methods have been previously
described (6). The study protocol was approved by the
institutional review board/ethics committee at each participating
site. All patients or their legally authorized representatives
provided written informed consent before enrollment. To
analyze a cohort with similar relationships between perfusion
deficits and outcomes, only anterior circulation occlusions were
included. To limit variability in the size of the at-risk territory,
M2 occlusions were excluded, leaving only internal carotid artery
(ICA) and middle cerebral artery (MCA) M1 occlusions in the
study cohort. Angiographic endpoints were core lab-adjudicated
and included TICI scores after each of the first three EmboTrap
passes and final TICI score after all interventions. TICI scoring
was inclusive of the 2c score (near complete or>90% reperfusion
of the downstream territory). Core lab readers were blinded to
clinical outcomes.
Statistical Analysis
Baseline characteristics were reported using standard descriptive
statistics. Parametric and non-parametric methods were applied
where appropriate.
The clinical impact of first-pass reperfusion was measured
controlling for final reperfusion grade. For example, among
subjects with final TICI score of 3, the subgroup where TICI 3
was achieved on the first pass was compared with the subgroup
requiring multiple passes. These subgroups were compared on
four efficacy and two safety outcomes. The primary efficacy
outcome was 90-day functional independence [modified Rankin
Scale (mRS) 0–2]. Additional efficacy outcomes were 90-day
freedom from disability (mRS 0–1), 90-day level of disability
(ordinal 6-level mRS), and dramatic early improvement [24-h
National Institutes of Health Stroke Scale (NIHSS) improvement
≥8 points]. Safety outcomes were symptomatic intracranial
hemorrhage (sICH) and 90-day mortality. Endpoints were
assessed using the Chi-squared, Fisher’s Exact, or Wilcoxon rank
sum test as appropriate. This analysis was similarly done for
subjects with final TICI 2c and separately 2b. Multiple logistic
regression analysis for 90-day mRS 0–2 was performed to assess
the impact of first-pass success adjusting for covariates with
univariate P < 0.1.
To explore the effect of final reperfusion extent on functional
outcome, 90-day mRS scores were compared between final
Frontiers in Neurology | www.frontiersin.org 2 May 2021 | Volume 12 | Article 669934
Yoo et al. First-Pass TICI 2c-3: Preferred Endpoint
TICI grades using the Jonckheere-Terpstra trend test. Receiver-
operating characteristic (ROC) analysis was used to identify the
optimal TICI threshold for discriminating 90-day mRS 0–2 and
0–1, and 24-h NIHSS improvement of 8 or more points.
The extent of reperfusion at procedure end that was most
strongly associated with outcomes was assessed by comparing:
substantial reperfusion (mTICI 2b-3), excellent reperfusion
(TICI 2c-3), and complete reperfusion (TICI 3). The extent
measure that nominally performed best was then further tested
to assess the impact of speed of attainment, by comparing
achievement on first, second, third, or fourth or higher passes.
Because the core lab assessed reperfusion after each of the first
three passes and at procedure end, all passes beyond the third
were aggregated into a single category. The effect of the number
of passes on 90-day mRS was evaluated using the Jonckheere-
Terpstra trend test. ROC analysis was used to identify the optimal
number of passes for predicting 90-day functional independence,
90-day freedom-from-disability and 24-h dramatic neurologic
improvement. In all ROC analyses, the optimal operating point
was defined as the point with the maximum Youden index
(=sensitivity + specificity − 1). Statistical significance was
defined as two-tailed P-value < 0.05.
Statistical analysis was performed using MedCalc Software
version 19 (Ostend, Belgium). The conclusions were verified
by an independent statistician using SAS version 9.4 software
(Cary, NC).
ARISE II was sponsored by Neuravi, Inc., currently
Cerenovus/Johnson & Johnson. This study is the academic
work of the authors. The sponsor played no role in the design
and conduct of the study; collection, management, analysis,
and interpretation of the data; preparation, review, or approval




Two hundred twenty-seven patients were treated with EmboTrap
in ARISE II. Nine basilar occlusion patients and 57 M2 occlusion
patients were removed for this analysis. Baseline characteristics
and outcomes are provided in Table 1. Of the 161 patients
meeting study entry criteria, 149 (92.5%) patients had substantial
reperfusion at procedure end (final TICI 2b-3): 28 (17.4%) final
TICI 2b; 42 (26.1%) final TICI 2c; and 79 (49.1%) final TICI 3.
Themedian number of thrombectomy passes was 2 [interquartile
range (IQR) 1–3], and the highest number of passes was 9.
Median procedural time was 44 (IQR 27–70) min.
Substantial reperfusion (TICI 2b-3) after the first pass was
seen in 81 (50.3%) patients: 19 (11.8%) first-pass TICI 2b; 18
(11.2%) first-pass TICI 2c; and 44 (27.3%) first-pass TICI 3. In
the remainder, there were 53 (32.9%) first-pass TICI 0–1 and
27 (16.8%) first-pass TICI 2a. Median procedural time from
groin puncture to achieving TICI ≥ 2b was 27 (IQR 22–38) min
in the subjects who had first-pass TICI 2b-3 vs. 61 (IQR 46–
86.5) min in those who achieved TICI 2b-3 after two or more
passes (P < 0.0001).
TABLE 1 | Baseline characteristics of study population (n = 161).
Variable
Age (years); mean ± SD 66.7 ± 13.3
Female sex; n (%) 92 (57.1%)
Baseline NIHSS score; median (IQR) 16 (13–20)
Baseline NCCT ASPECTS; median (IQR) (n = 124) 10 (10–10)
Occlusion level; n (%)
ICA 35 (21.7%)
MCA M1 126 (78.3%)
IV tPA treatment; n (%) 106 (65.8%)
Hypertension; n (%) 107 (66.5%)
Diabetes mellitus; n (%) 31 (19.3%)
Atrial fibrillation; n (%) 62 (38.5%)
Dyslipidemia; n (%) 63 (39.1%)
Smoking; n (%) 42 (26.1%)
Previous stroke/transient ischemic attack; n (%) 29 (18.0%)
Previous MI/CAD; n (%) 35 (21.7%)
Clinical and safety outcomes
24-h NIHSS score; median (IQR) (n = 155) 4 (1–14)
Dramatic neurologic improvement [Baseline to 24-h
NIHSS score improvement ≥ 8 points; n (%)]
94/155 (60.6%)
90-day disability level mRS; median (IQR) (n = 156) 1.5 (0–4)
90-day functional independence, mRS 0–2; n (%) 103/156 (66.0%)
90-day freedom-from-disability, mRS 0–1; n (%) 78/156 (50.0%)
90-day mortality; n (%) 14/156 (9.0%)
sICH; n (%) 10 (6.2%)
SD, standard deviation; NIHSS, National Institutes of Health Stroke Scale; IV tPA,
intravenous tissue plasminogen activator; IQR, interquartile range; MI/CAD, myocardial
infarction/coronary artery disease; mRS, modified Rankin Scale; NCCT ASPECTS,
non-contrast CT Alberta Stroke Program Early CT Score; sICH, symptomatic
intracranial hemorrhage.
First-Pass Success vs. Multiple Passes:
Final Angiographic and Clinical Outcomes
Supplementary Material enumerates the breakdown of final
TICI results based on the first pass TICI score. When controlling
for final reperfusion grade, there were significantly better 90-
day ordinal mRS outcomes among patients who achieved their
final TICI score on the first pass compared to multiple passes
(Figure 1). For final TICI 2b, the median 90-day mRS scores
were 1 (IQR 0–3) vs. 3 (IQR 2–4) for the first-pass group vs. the
multiple-pass group (P = 0.04). For final TICI 2c, the median
90-day mRS scores were 0 (IQR 0–2) vs. 2 (IQR 1–4) (first-pass
group vs. the multiple-pass group; P = 0.004). For final TICI
3, the median 90-day mRS scores were 1 (IQR 0–2) vs. 2 (IQR
1–5) (first-pass group vs. the multiple-pass group; P = 0.01).
There were no significant differences among the first-pass and
multiple-pass groups for sICH and for 90-daymortality, although
there were numerically more safety events in the multiple-pass
groups in most cases (Table 2). After adjusting for age, baseline
NIHSS score, baseline Alberta Stroke Program Early Computed
Tomography Score (ASPECTS), vessel occlusion level, atrial
fibrillation, and final TICI 2c-3 score, first-pass success (i.e.,
when the final TICI score is achieved on the first pass) was an
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FIGURE 1 | Distribution of 90-day mRS scores comparing first-pass reperfusion vs. multiple-pass reperfusion. Results are shown for (A) final TICI 2b: median 90-day
mRS scores were 1 (IQR 0-3) vs. 3 (IQR 2–4) for the first-pass group vs. the multiple-pass group (P = 0.04); (B) final TICI 2c: median 90-day mRS scores were 0 (IQR
0–2) vs. 2 (IQR 1–4) for the first-pass group vs. the multiple-pass group (P = 0.004); and (C) final TICI 3 patients: median 90-day mRS scores were 1 (IQR 0–2) vs. 2
(IQR 1–5) for the first-pass group vs. the multiple-pass group (P = 0.01).
independent predictor of 90-day mRS 0–2 [odds ratio (OR) 3.42
(95% CI, 1.27–9.17), P = 0.01]. The associations between the
baseline variables and both 90-day mRS 0–2 and final TICI 2c-3
are provided in Supplementary Material.
Optimal Final TICI Score for Discriminating
Good Clinical Outcome
90-day functional outcome was significantly better with greater
final reperfusion extent (Figure 2). Median 90-day mRS was 1
(IQR 0–3.25) for final TICI 3, 1.5 (IQR 0–3) for TICI 2c, 2
(IQR 1–4) for TICI 2b, and 3.5 (IQR 2–4.5) for TICI 0-2a (P
< 0.05; Jonckheere-Terpstra trend test). Final TICI 2c-3 showed
the highest nominal accuracy for discriminating 90-day mRS 0–
2 (sensitivity 79.6%, specificity 34.0%) and mRS 0–1 (sensitivity
83.3%, specificity 33.3%), and 24-h NIHSS improvement ≥8
points (sensitivity 80.9%, specificity 34.4%).
Optimal Number of Passes for Achieving
Final TICI 2c-3
The median number of passes for patients with final TICI 2c-3
was one (IQR 1–3). Figure 3A illustrates the relationship between
number of passes for achieving TICI 2c-3 and 90-day functional
outcome. Median 90-day mRS was 1 (IQR 0–2) for one pass,
1 (IQR 1–4) for two passes, 2 (IQR 1–4) for three passes, and
2 (IQR 1–5) for four or more passes (P = 0.0001; Jonckheere-
Terpstra trend test). Median procedure time for one pass was
25 (IQR 20–34) min, for two passes was 44 (IQR 35–57.5) min,
for three passes was 60 (IQR 48–64) min, and for four or more
passes was 76 (IQR 64.5–105) min (P < 0.00001; Jonckheere-
Terpstra trend test). One pass showed the highest nominal
accuracy for discriminating 90-day mRS 0–2 (sensitivity 58.5%,
specificity 68.6%) and 24-h NIHSS score improvement≥8 points
(sensitivity 56.6%, specificity 62.5%). Importantly, there were no
significant imbalances in the baseline variables between first-pass
TICI 2c-3 and non-first-pass TICI 2c-3 (Table 3). Two or fewer
passes was the optimal threshold for discriminating 90-day mRS
0–1 (sensitivity 80.0%, specificity 46.2%).
Regarding safety, each subsequent pass required to achieve
TICI 2c-3 was associated with higher mortality: 90-day mortality
was 5.1% (3/59) for one pass, 9.5% (2/21) for two passes, 16.7%
(3/18) for three passes, and 21.1% (4/19) for four or more passes
(P = 0.03, Chi-squared trend test). For comparison, mortality
in those without reperfusion (TICI 0-2a) was 16.7%. There was
no significant relationship between number of passes and sICH.
Rates of sICH were 1.6% (1/62) for one pass, 4.8% (1/21) for two
passes, 10.5% (2/19) for three passes, and 5.3% (1/19) for four or
more passes (P= 0.20, Chi-squared trend test). The sICH rate for
TICI 0-2a patients was 25% (3/12).
The impact of the number of passes to final TICI 2c-3 on
90-day outcome is shown separately for patients treated early
from stroke onset (≤4 h to groin puncture) vs. late (>4 h) in
Supplementary Material.
Likelihood of Achieving Final TICI 2c-3
Based on First-Pass Result
There was a significantly higher chance of achieving TICI 2c-3
on the first pass [38.5% (62/161)] compared to after the first pass
[27.1% (59/217); P = 0.02]. Furthermore, if the first pass did not
result in TICI 2c-3 and further attempts were performed, there
was a higher chance of achieving final TICI 2c-3 when the first
pass yielded a lower reperfusion grade. Rates of final TICI 2c-
3 were 71.7% (38/53) for first-pass TICI 0-1, 55.6% (15/27) for
first-pass TICI 2a, and 50% (6/12) for first-pass TICI 2b (P =
0.08; Chi-squared test for trend). There were more overall passes
for lower first-pass TICI scores: median 3 (IQR 3–5) for first-
pass TICI 0–1 vs. 3 (IQR 2–3) for first-pass TICI 2a vs. 2 (IQR
2–2.5) for first-pass TICI 2b (P = 0.0004; Jonckheere-Terpstra
trend test).
DISCUSSION
Core-lab adjudicated ARISE II data confirm the superior clinical
benefit of first-pass reperfusion. When adjusting for final TICI
score, first-pass success (defined as when the final TICI score
of 2b-3 is achieved on the first pass) yielded significantly better
90-day functional outcomes and was an independent predictor
of 90-day independence. Furthermore, first-pass TICI 2c-3 was
the optimal combination of reperfusion extent and speed for
predicting good outcome after IAT. These findings were similar
when restricting the analysis to subjects who received 3 or fewer
passes with EmboTrap.
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The FPE has been variably defined as first-pass TICI 3 and
more recently first-pass TICI 2c-3 (8–10). Our study supports the
inclusion of 2c scores [defined in ARISE II as >90% anterograde
reperfusion (1)] into a standardized FPE definition. Final TICI
2c-3 was achieved in 75.2% of the study cohort compared to
49.1% for TICI 3 alone and provided the best discrimination of
good and excellent 90-day functional outcomes (mRS 0–1 and
0–2) and early dramatic neurologic improvement (24-h NIHSS
improvement≥8 points). This mirrors previous reports that have
found similar outcomes between TICI 2c and 3 reperfusion (11,
12). In an ancillary analysis of the ASTER trial, the magnitude
of benefit for achieving 90-day mRS 0–2 was congruent between
TICI 2c and 3 relative to TICI 2b, and combined TICI 2c-3
patients had a significantly higher rate of favorable outcomes
compared to 2b patients [OR 1.72 (95% CI, 1.01–2.90)] (12).
Another endpoint used in recent studies is first-pass TICI
2b-3, termed modified FPE (8, 9). A major limitation of this
endpoint is that TICI 2b encompasses an overly broad range of
reperfusion results (50–89% of the ischemic territory), many of
which might be considered suboptimal currently. It is likely for
this reason that the majority of first-pass TICI 2b patients [12/19
(63%)] underwent additional passes, questioning the clinical
relevance of this first-pass category. There may be potential value
of the expanded TICI (eTICI) scale, which subdivides TICI 2b
grades into eTICI 2b50 (50–66% reperfusion) and 2b67 (67–
89% reperfusion). In the HERMES dataset, the c-statistic for
discriminating 90-day mRS 0–2 was slightly higher for eTICI
(0.664) compared to the TICI classification employed in ARISE
II (0.661), the only difference being the 2b67 categorization (13).
Future studies should investigate whether a reformulation of FPE
to include eTICI 2b67 results is warranted.
An additional argument against including TICI 2b scores into
the FPE definition is the issue of clot fragmentation, which can
impede full reperfusion. Our analysis revealed a numerically
lower likelihood of achieving TICI 2c-3 when the first pass
yielded TICI 2b compared to a lesser score. Among patients who
underwentmultiple passes, there was a stepwise reduction in final
TICI 2c-3 rate from a first-pass TICI score of 0–1 (72%) to 2a
(56%) to 2b (50%) (P = 0.08). This observation likely owes to the
smaller, more distal vessel segments that remain occluded when
there is greater partial reperfusion, which are more difficult and
riskier to treat. This increased risk may explain why there were
fewer passes performed after first-pass TICI 2a and fewer still
after TICI 2b compared to TICI 0–1. In this context, both TICI
2a and 2b may be viewed as unwelcome indicators of thrombus
fragmentation. Thrombus friability likely plays a central role in
cases of distal embolization, and techniques should be targeted to
minimize this phenomenon.
The optimal speed for attaining TICI 2c-3 was one
thrombectomy pass (first-pass TICI 2c-3), which was observed
in 51.2% of final TICI 2c-3 patients and best predicted 90-day
good outcome and early dramatic neurological improvement
compared to other numbers of passes. There was a worsening
of clinical outcomes with each additional pass, consistent with
prior work showing that procedural time to reperfusion is
a powerful predictor of IAT outcomes (7). With regards to
benchmarking device performance, the number of passes is a
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FIGURE 2 | Box-whisker plots showing median 90-day mRS vs. final TICI grade. There are significantly lower mRS scores with greater final reperfusion (P < 0.05;
Jonckheere-Terpstra trend test).
more suitable measure of device-related revascularization speed
than procedure time because it disregards the time required for
vessel catheterization, a delay which is unrelated to device action
and can be highly variable (14).
A substantial proportion of study patients required three
or more thrombectomy passes (37% in the entire cohort, and
31% among those achieving final TICI 2c-3). In refractory
cases, an important question facing neurointerventionists is how
many passes should be performed before stopping. A recent
study of stent retriever thrombectomy reported dismal outcomes
after the third pass (7.4% rate of 90-day mRS 0–2 for passes
4 through 8) despite an ∼25% per-pass rate of TICI 2b-3
(15). Conversely, another study of largely stent retrievers (95%)
found a significantly higher rate of good outcome in patients
who achieved TICI 2b-3 on the fourth pass compared to non-
reperfusers (16). Our analysis also suggests clinical value in
pursuing more than three passes. First, even though the chance
of achieving TICI 2c-3 dropped after the first pass, there was still
a 30% per-pass rate of TICI 2c-3 among passes 3 or greater. And
when TICI 2c-3 is achieved, there are higher rates of 90-day mRS
0–2 and 0–1 (Figures 3A–C) for every pass number, including
four or higher, compared to non-reperfusers (final TICI 0-
2a). Although many of these per-pass comparisons were not
statistically significant, this may be due to small sample sizes. The
clinical value of near-complete/complete reperfusion achieved
in a delayed fashion is consistent with other studies showing
that complete reperfusion mitigates the deleterious effect of
treatment delay (16, 17). In addition, there were no obvious
safety concerns with pursuing more than three passes. Although
mortality increased with each additional pass required to achieve
TICI 2c-3, the mortality associated with 4 or more passes
(21.1%) was comparable to that seen in non-reperfusers (16.7%).
Concerning sICH, there was no significant association with pass
number, and the rate of sICH with 4 or more passes (5.3%) was
lower than that seen in non-reperfusers (25%). Previous reports
are contradictory regarding the relationship between the number
of passes and hemorrhagic conversion (18, 19).
Study limitations include use of a single device for the first
three thrombectomy passes, which may limit generalizability.
However, it is likely that the principal findings regarding
the relationship between clinical outcome and the extent and
speed of reperfusion are independent of how this reperfusion
is achieved. Another limitation is that the study cohort
comprised largely ideal treatment candidates, as reflected in their
baseline ASPECTS scores (76% with ASPECTS 10). As such,
the outstanding outcomes reported here (66% mRS 0–2 and
50% mRS 0–1 at 90 days) do not reflect real-world practice.
These limitations stem from the ARISE II study design as a
prospective registration trial for FDA approval of EmboTrap.
However, this design also lent numerous strengths to the analysis,
including rigorous data collection and monitoring, minimal
subject attrition (3% at 90 days), and strict core lab adjudication
of reperfusion results. Unlike previous thrombectomy studies,
the ARISE II core lab prospectively evaluated each of the first
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FIGURE 3 | 90-day outcomes vs. the number of passes required to reach final TICI 2c-3 reperfusion. (A) 90-day mRS: There are significantly lower mRS scores with
fewer passes (P = 0.0001; Jonckheere-Terpstra trend test). (B) 90-day mRS 0–2: There are progressively lower rates of good outcome with increasing number of
passes (P = 0.005; Chi-squared test for trend). Asterisk indicates significant difference compared to non-reperfusers (final TICI 0-2a). (C) 90-day mRS 0–1: There are
progressively lower rates of excellent outcome with increasing number of passes (P = 0.003; Chi-squared test for trend). Asterisk indicates significant difference
compared to non-reperfusers (final TICI 0-2a).
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TABLE 3 | Comparison of baseline variables between first-pass TICI 2c-3 vs. non-first-pass TICI 2c-3.
Variable FP TICI 2c-3 (n = 62) Non-FP TICI 2c-3 (n = 59) P-value
Age (years); mean ± SD 67.2 ± 12.8 66.6 ± 14.0 0.78
Female sex; n (%) 36 (58.1%) 36 (61.0%) 0.74
Baseline NIHSS score; median (IQR) 16.5 (12–19) 17 (14–21) 0.36
Baseline NCCT ASPECTS; median (IQR) (n = 94) 10 (9.5–10) (n = 48) 10 (9–10) (n = 46) 0.80
Occlusion level; n (%)
ICA 14 (22.6%) 13 (22.0%) 0.94
MCA M1 48 (77.4%) 46 (78.0%)
IV tPA treatment; n (%) 38 (61.3%) 44 (74.6%) 0.12
Hypertension; n (%) 44 (71.0%) 40 (67.8%) 0.71
Diabetes mellitus; n (%) 12 (19.4%) 11 (18.6%) 0.92
Atrial fibrillation; n (%) 22 (35.5%) 25 (42.4%) 0.44
Dyslipidemia; n (%) 22 (35.5%) 26 (44.1%) 0.34
Smoking; n (%) 13 (21.0%) 18 (30.5%) 0.23
Previous stroke/transient ischemic attack; n (%) 11 (17.7%) 9 (15.3%) 0.71
Previous MI/CAD; n (%) 18 (29.0%) 11 (18.6%) 0.18
FP, first-pass; IV tPA, intravenous tissue plasminogen activator; IQR, interquartile range; MI/CAD, myocardial infarction/coronary artery disease; NCCT ASPECTS, non-contrast CT
Alberta Stroke Program Early CT Score; NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation; TICI, Treatment in Cerebral Ischemia scale.
three thrombectomy passes, yielding novel core lab-adjudicated
data concerning reperfusion speed.
CONCLUSIONS
Data from ARISE II underscore the critical impact of procedural
time to reperfusion on clinical outcomes after thrombectomy.
First-pass TICI 2c-3 provides the optimal measure of both
extent and speed of reperfusion for predicting good functional
outcome and may serve as a useful benchmark for testing device
performance and thrombectomy techniques in future studies.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included
in the article/Supplementary Material, further inquiries can be
directed to the corresponding author/s.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by the institutional review board/ethics committee at
each participating site. The patients/participants provided their
written informed consent to participate in this study.
AUTHOR CONTRIBUTIONS
AY contributed to the conceptualization, methodology, software,
formal analysis, and writing of the original draft of the
manuscript. AY, TA, JSa, MR, HB, GD, DL, AJ, HM, OZ, and
ARISE II Investigators participated in the investigation and
provided resources and project administration. JSo contributed
to the data visualization. AY, TA, JSa, MR, HB, HM,
and OZ provided study supervision. AY, JSo, TA, JSa,
MR, HB, GD, DL, AJ, HM, and OZ contributed to the
review and editing of the final draft of the manuscript.
All authors contributed to the article and approved the
submitted version.
ACKNOWLEDGMENTS
Cerenovus sponsored the ARISE II study, and provided support
for open access to this article.
SUPPLEMENTARY MATERIAL




1. Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, von Kummer R, Saver
JL, et al. Recommendations on angiographic revascularization
grading standards for acute ischemic stroke: a consensus statement.
Stroke. (2013) 44:2650–63. doi: 10.1161/STROKEAHA.113.0
01972
2. Yoo AJ, Simonsen CZ, Prabhakaran S, Chaudhry ZA, Issa MA, Fugate
JE, et al. Refining angiographic biomarkers of revascularization: improving
outcome prediction after intra-arterial therapy. Stroke. (2013) 44:2509–
12. doi: 10.1161/STROKEAHA.113.001990
3. BerkhemerOA, Fransen PS, BeumerD, van den Berg LA, LingsmaHF, YooAJ,
et al. A randomized trial of intraarterial treatment for acute ischemic stroke.
N Engl J Med. (2015) 372:11–20. doi: 10.1056/NEJMoa1411587
4. Goyal M,Menon BK, van ZwamWH, Dippel DW,Mitchell PJ, Demchuk AM,
et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-
analysis of individual patient data from five randomised trials. Lancet. (2016)
387:1723–31. doi: 10.1016/S0140-6736(16)00163-X
Frontiers in Neurology | www.frontiersin.org 8 May 2021 | Volume 12 | Article 669934
Yoo et al. First-Pass TICI 2c-3: Preferred Endpoint
5. Yoo AJ, Andersson T. Thrombectomy in acute ischemic stroke: challenges to
procedural success. J Stroke. (2017) 19:121–30. doi: 10.5853/jos.2017.00752
6. Zaidat OO, Bozorgchami H, Ribo M, Saver JL, Mattle HP, Chapot R,
et al. Primary results of the multicenter ARISE II study (analysis of
revascularization in ischemic stroke with EmboTrap). Stroke. (2018) 49:1107–
15. doi: 10.1161/STROKEAHA.117.020125
7. Alawieh A, Vargas J, Fargen KM, Langley EF, Starke RM, De Leacy R, et al.
Impact of procedure time on outcomes of thrombectomy for stroke. J Am Coll
Cardiol. (2019) 73:879–90. doi: 10.1016/j.jacc.2018.11.052
8. Zaidat OO, Castonguay AC, Linfante I, Gupta R, Martin CO, Holloway WE,
et al. First Pass Effect: A New Measure for Stroke Thrombectomy Devices.
Stroke. (2018) 49:660–6. doi: 10.1161/STROKEAHA.117.020315
9. Zaidat OO, Mueller-Kronast NH, Hassan AE, Haussen DC, Jadhav AP,
Froehler MT, et al. Impact of balloon guide catheter use on clinical and
angiographic outcomes in the STRATIS stroke thrombectomy registry. Stroke.
(2019) 50:697–704. doi: 10.1161/STROKEAHA.118.021126
10. Nikoubashman O, Dekeyzer S, Riabikin A, Keulers A, Reich
A, Mpotsaris A, et al. True first-pass effect. Stroke. (2019)
50:2140–46. doi: 10.1161/STROKEAHA.119.025148
11. Tung EL, McTaggart RA, Baird GL, Yaghi S, Hemendinger M, Dibiasio
EL, et al. Rethinking thrombolysis in cerebral infarction 2b: which
thrombolysis in cerebral infarction scales best define near complete
recanalization in the modern thrombectomy era? Stroke. (2017) 48:2488–
93. doi: 10.1161/STROKEAHA.117.017182
12. Dargazanli C, Fahed R, Blanc R, Gory B, Labreuche J, Duhamel A,
et al. Modified thrombolysis in cerebral infarction 2C/thrombolysis
in cerebral infarction 3 reperfusion should be the aim of
mechanical thrombectomy: insights from the ASTER trial (contact
aspiration versus stent retriever for successful revascularization).
Stroke. (2018) 49:1189–96. doi: 10.1161/STROKEAHA.118.0
20700
13. Liebeskind DS, Bracard S, Guillemin F, Jahan R, Jovin TG, Majoie CB,
et al. eTICI reperfusion: defining success in endovascular stroke therapy.
J Neurointerv Surg. (2019) 11:433–38. doi: 10.1136/neurintsurg-2018-0
14127
14. Ribo M, Flores A, Rubiera M, Pagola J, Mendonca N, Rodriguez-Luna D,
et al. Difficult catheter access to the occluded vessel during endovascular
treatment of acute ischemic stroke is associated with worse clinical outcome. J
Neurointerv Surg. (2013) 5 (Suppl. 1):i70–3. doi: 10.1136/neurintsurg-2012-0
10438
15. Flottmann F, Leischner H, Broocks G, Nawabi J, Bernhardt M,
Faizy TD, et al. Recanalization rate per retrieval attempt in
mechanical thrombectomy for acute ischemic stroke. Stroke. (2018)
49:2523–5. doi: 10.1161/STROKEAHA.118.022737
16. Garcia-Tornel A, Requena M, Rubiera M, Muchada M, Pagola
J, Rodriguez-Luna D, et al. When to stop. Stroke. (2019)
50:1781–8. doi: 10.1161/STROKEAHA.119.025088
17. Prabhakaran S, Castonguay AC, Gupta R, Sun CJ, Martin CO, Holloway
W, et al. Complete reperfusion mitigates influence of treatment time
on outcomes after acute stroke. J Neurointerv Surg. (2017) 9:366–
9. doi: 10.1136/neurintsurg-2016-012288
18. Bourcier R, Saleme S, Labreuche J, Mazighi M, Fahed R, Blanc R, et al.
More than three passes of stent retriever is an independent predictor of
parenchymal hematoma in acute ischemic stroke. J Neurointerv Surg. (2019)
11:625–9. doi: 10.1136/neurintsurg-2018-014380
19. Hassan AE, Kotta H, Shariff U, Preston L, Tekle W, Qureshi A. There
is no association between the number of stent retriever passes and the
incidence of hemorrhagic transformation for patients undergoing mechanical
thrombectomy. Front Neurol. (2019) 10:818. doi: 10.3389/fneur.2019.00818
Conflict of Interest: AY is a consultant for Cerenovus, Penumbra, and Zoll,
receives research grants from Medtronic, Cerenovus, Penumbra, Stryker, and
Genentech, and has equity interest in Insera Therapeutics. TA is a consultant for
Neuravi, Ablynx, Amnis Therapeutics, Medtronic, Rapid Medical, and Stryker.
The University of California, Regents receives funding for JSa’s services as a
scientific consultant regarding trial design and conduct for Covidien and Stryker;
JSa is an employee of the University of California, which holds a patent on
retriever devices for stroke. MR is a shareholder in Anaconda Biomed, consultant
for Cerenovus, Medtronic, Stryker, Apta Targets, and Vesalio. HB serves as a
modest consultant for Cerenovus/Neuravi, and Stryker. GD serves as a consultant
for Medtronic, Microvention, Penumbra, and Cerenovus. DL serves as an imaging
core lab consultant for Cerenovus, Genentech, Medtronic, Stryker, and Vesalio.
HM reports personal fees from Covidien/Medtronic, Neuravi/Cerenovus, Servier,
and Bayer outside the submitted work, and served on the steering committees
of the SWIFT PRIME and ARISE studies. OZ serves as a consultant for Neuravi,
Stryker, Penumbra, and Medtronic.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2021 Yoo, Soomro, Andersson, Saver, Ribo, Bozorgchami, Dabus,
Liebeskind, Jadhav, Mattle and Zaidat. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 9 May 2021 | Volume 12 | Article 669934
